Sol-Gel Technologies (SLGL) EBIT Margin (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly EBIT Margin of 3569.44% for Q1 2026, up 268981.0% year-over-year from N/an in Q1 2025, and up 828.33% quarter-over-quarter from 490.09% in Q4 2025.
Sol-Gel Technologies (SLGL) EBIT Margin (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported EBIT Margin for 9 consecutive years, with 3569.44% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT Margin rose 268981.0% year-over-year to 3569.44%; the TTM figure through Mar 2026 stood at 29.17% (down 195.0% YoY), while the FY2025 annual figure was 38.88%, up 6525.0% from the prior year.
- EBIT Margin rose to 3569.44% in Q1 2026 per SLGL's latest filing, from 490.09% in the prior quarter.
- Across five years, EBIT Margin topped out at 3569.44% in Q1 2026 and bottomed at 6205.0% in Q4 2022.
- Historically, EBIT Margin has averaged 838.49% across 5 years, with a median of 490.09% in 2025.
- Annual changes were most pronounced in 2022 — EBIT Margin sank 627208 bps — and 2023, when it surged 499538 bps.
- Sol-Gel Technologies' EBIT Margin stood at 6205.0% in 2022, then soared by 81 bps to 1209.62% in 2023, then sank by 81 bps to 2193.88% in 2024, then jumped by 78 bps to 490.09% in 2025, then soared by 828 bps to 3569.44% in 2026.
- Business Quant data shows SLGL's EBIT Margin at 3569.44% in Q1 2026, 490.09% in Q4 2025, and 1572.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 3,569.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,569.44% |
| Dec 31, 2025 | -490.09% |
| Sep 30, 2025 | -1,572.00% |
| Jun 30, 2025 | 65.06% |
| Mar 31, 2025 | 879.63% |
| Dec 31, 2024 | -2,193.88% |
| Sep 30, 2024 | -15.44% |
| Jun 30, 2024 | 29.89% |
| Dec 31, 2023 | -1,209.62% |
| Sep 30, 2023 | -2,961.03% |
| Jun 30, 2023 | -1,098.82% |
| Dec 31, 2022 | -6,205.00% |
| Sep 30, 2022 | -1,388.89% |
| Jun 30, 2022 | 13.16% |
| Mar 31, 2022 | 0.20% |
| Dec 31, 2021 | 67.08% |
| Sep 30, 2021 | 95.21% |
| Jun 30, 2021 | 866.59% |
| Mar 31, 2021 | 602.57% |
| Dec 31, 2020 | -324.99% |